Moleculin Biotech, Inc. (LON:0K2H)

Market Cap	3.04M
Revenue (ttm)	n/a
Net Income (ttm)	-22.49M
Shares Out	n/a
EPS (ttm)	-8.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,990
Average Volume	56,710
Open	1.286
Previous Close	1.409
Day's Range	1.261 - 1.320
52-Week Range	1.271 - 11.867
Beta	n/a
RSI	44.19
Earnings Date	Mar 21, 2025

About Moleculin Biotech

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription fact...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 18
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0K2H

Financial Performance

Financial numbers in USD